Hot flashes are perceived by up to 80% of women and about 25% are frequent and severe. Not only women in menopause suffer from them, but others with a special risk profile, such as breast cancer survivors who receive hormone cancellation treatment.
For a product to be marketed in Spain, it must pass the approval of the EMA (European Medicines Agency), which is expected by the end of the year. The drug is already tested by Spanish women, but clinical trials in clinical trials continues.